Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julian Adams

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Oncotarget|October 4, 2014
Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73Frankie Lam, Abdullahi Y Abbas, Hao Shao, et al.
The Journal of Biological Chemistry|October 14, 2010
Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivoBonnie Tillotson, Kelly Slocum, John Coco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R Berenson, Hank H Yang, Karen Sadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian, Steven Soignet, Don S Dizon, et al.
Cancer Research|September 5, 2002
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modelRichard LeBlanc, Laurence P Catley, Teru Hideshima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphomaOwen A O'Connor, John Wright, Craig Moskowitz, et al.
Molecular Cancer Therapeutics|December 3, 2009
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivoMark Douglas, Alice R Lim, James R Porter, et al.
Journal of Medicinal Chemistry|July 21, 2006
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90Jie Ge, Emmanuel Normant, James R Porter, et al.
Journal of Medicinal Chemistry|January 30, 2014
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activitiesTiangong Lu, Aik Wye Goh, Mingfeng Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agentsMark H Ma, Hank H Yang, Kimberly Parker, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Oncotarget|October 4, 2014
Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73Frankie Lam, Abdullahi Y Abbas, Hao Shao, et al.
The Journal of Biological Chemistry|October 14, 2010
Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivoBonnie Tillotson, Kelly Slocum, John Coco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R Berenson, Hank H Yang, Karen Sadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian, Steven Soignet, Don S Dizon, et al.
Cancer Research|September 5, 2002
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modelRichard LeBlanc, Laurence P Catley, Teru Hideshima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphomaOwen A O'Connor, John Wright, Craig Moskowitz, et al.
Molecular Cancer Therapeutics|December 3, 2009
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivoMark Douglas, Alice R Lim, James R Porter, et al.
Journal of Medicinal Chemistry|July 21, 2006
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90Jie Ge, Emmanuel Normant, James R Porter, et al.
Journal of Medicinal Chemistry|January 30, 2014
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activitiesTiangong Lu, Aik Wye Goh, Mingfeng Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agentsMark H Ma, Hank H Yang, Kimberly Parker, et al.
Pageof 7